OKG-0301 is a novel ribonuclease that can enter host cells and preferentially degrade viral tRNA leading to an inhibition of protein synthesis. This is an evaluation of the anti-adenoviral efficacy of topical OKG-0301 in the Ad5/NZW rabbit ocular model.
This article from Review of Ophthamology is a discussion of the various causes of conjunctivitis, and new therapeutic approaches on the horizon.
Okogen, Inc., a developer of ophthalmic anti-infectives has secured Ora, Inc., the leading ophthalmic Contract Research Organization, to conduct the clinical studies and lead the regulatory strategy of OKG-0301 for the treatment of adenoviral conjunctivitis.
© 2023 Okogen, Inc. All Rights Reserved
United States
Okogen, Inc.
332 Encinitas Blvd. Suite 102
Encinitas, CA 92024, USA
Australia
Okogen Pty Ltd
Level 9, 31 Queen St
Melbourne, VIC 3000 AUS
